What's on

  • June 7, 2019

    A new molecular mechanism could explain the origins of the depressive symptoms in Huntington’s disease

    About 40 % of the affected patients with Huntington’s disease –a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of the typical motor symptoms of the disease. An altered function of Cdk5 kinase –an essential enzyme in several cell signalling pathways- could explain the physiopathology of the depressive-like behaviour in Huntington’s disease, according to a pre-clinical study in which Sílvia Ginés, Verónica Brito, Albert Giralt and Jordi Alberch from the Faculty of Medicine and Health Sciences, the Institute of Neurosciences of the UB (UBNeuro) and researchers of the Pathophysiology and treatment of neurodegenerative disorders IDIBAPS research group, have taken part.

    Read the rest of this entry

  • May 15, 2019

    Cerium oxide nanoparticles for liver cancer treatment

    PromeCean, a new project aiming to apply nanoparticles to the treatment of liver cancer has been launched by the ICN2 and the Institut d’Investigacions Biomèdiques Pi i Sunyer in May 2019. Cofounded by the European Regional Development Fund (ERDF) in the framework of the FEDER Operative Programme of Catalonia 2014-2020, this research will focus on developing and testing a pharmaceutical product based on cerium oxide nanoparticles to treat hepatocellular carcinoma.

    Read the rest of this entry

  • April 17, 2019

    A protein involved in cancer protects against muscle diseases

    Researchers from the IDIBAPS Research Institute have found that the protein known as ZEB1 have beneficial or deleterious effects depending on its levels and the tissue where is expressed. Previous studies from the same group had shown that the uncontrolled increase of ZEB1 contributes to the development of different types of cancers. However, the new studies from the group show that ZEB1 protects the muscle from atrophy and muscular dystrophy.

    Read the rest of this entry

  • April 2, 2019

    Anti-platelet therapy prevents the progression of fatty liver to liver cancer in animal models

    A study published in the journal Nature Medicine proposes a paradigm shift in the approach to steatohepatitis, the most advanced degree of non-alcoholic fatty liver disease, one of the diseases responsible for the increase in the incidence of liver cancer.

    Read the rest of this entry

  • March 5, 2019

    Researchers at IDIBAPS describe how aging aggravates liver diseases

    IDIBAPS researchers have published a series of three studies in which describe the impact of aging on the liver biology and function, both in healthy individuals and in the context of different liver diseases. The works show that the progression and response to treatments is not the same in older people as in young people, demonstrating that aging causes a faster aggravation of liver disease and a worse response to therapies. In addition, it is described for the first time that the molecular signature of liver disease is different in older patients compared to young people.

    Read the rest of this entry

PreviousNext